Supernus Pharmaceuticals (SUPN) Selling Expense — Quarterly & Annual

Screener

Selling Expense at other companies

Abercrombie & FitchANF

$431.2M+7.8%

OFL

Omega FlexOFLX

$5.49M+9.9%

JAK

Jakks PacificJAKK

$8.16M-6.1%

Alaska Air GroupALK

$115M+9.5%

Lindsay CorporationLNN

$10.32M+1.0%

CVD Equipment Corp.CVV

$240K-34.6%

Segments

By segment

Reportable Segment$66.28M+55.5%

Other financials

Income statement

Revenue$207.7M+38.6%

Gross profit$184.3M+37.5%

Operating income-$8.3M+18.8%

Net income-$2.3M+80.6%

EPS (diluted)-$0.04+81.0%

Balance sheet

Cash & equivalents$186.3M+60.8%

Total debt$40.9M+26.6%

Total equity$1.1B+4.5%

Total assets$1.5B+11.4%

Cash flow

Operating cash flow$66.5M+117%

CapEx--100%

Free cash flow$66.5M+120%

Valuation

Market cap$2.77B+21.8%

Enterprise value$2.63B+21.5%

P/S3.6×+0.1×

Profitability

Gross margin89.4%+1.0pp

Operating margin-7.8%-18.9pp

Net margin-3.7%-13.0pp

FCF margin27.9%+3.4pp

Returns & leverage

Return on equity-2.8%-9.1pp

Debt / equity0×0.0×

Current ratio2×-0.5×